Ow Karla V, Vo Ann, Cunningham Jonathan
From The University of Texas MD Anderson Cancer Center, Houston, Texas.
J Adv Pract Oncol. 2024 Feb 14:1-12. doi: 10.6004/jadpro.2024.15.8.3.
T-cell lymphomas (TCLs) have a unique pathobiology, clinically aggressive course, and poor prognosis. Recently, there have been significant advances in understanding the molecular genetic alterations of TCLs through next-generation sequencing. This has led to the development of specific therapeutic molecules. This review aims to provide an up-to-date overview of the current therapeutic approaches for the subtype peripheral T-cell lymphoma, not otherwise specified.
T细胞淋巴瘤（TCLs）具有独特的病理生物学特性、临床侵袭性病程及不良预后。近来，通过新一代测序技术，在了解TCLs的分子遗传学改变方面取得了重大进展。这促使了特异性治疗分子的研发。本综述旨在提供关于外周T细胞淋巴瘤（未另行说明的亚型）当前治疗方法的最新概述。
